You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 31 - 40 of 10972 results
  1. In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease

    SBC: VINCERE BIOSCIENCES INC            Topic: 999

    ABSTRACT Existing treatments for Parkinson’s disease (PD), which affects 10 million people worldwide, primarily augment dopaminergic neurotransmission to provide symptomatic benefit. No current therapy can slow or stop the progression of PD. We propose a drug discovery platform to develop small molecules targeting the parkin-USP30 mitophagy pathway, which represents a key regulator of mitochondr ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Clarity in Motion: A Motion-Tolerant Aid for Selectively Hearing Acoustic Sources

    SBC: Speech Technology and Applied Research Corporation            Topic: NIDCD

    Noisy rooms with multiple moving sound sources create problems for hearing-impaired listeners. Unwanted masking sounds reduce the intelligibility of speech and other sounds listeners want to hear. “Source Separation” signal processing methods are known that extract important sources and “scrub” unwanted noise, but these methods typically require the acoustic sensors (microphones) and sourc ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. STI NG Plus, a Swab to Answer Molecular Panel Test for Point of Care Diagnosis and Treatment Recommendation

    SBC: AMPLIFIDX INC            Topic: NIAID

    ABSTRACT The need to develop sensitive, specific, and more easily available point-of-care technologies for diagnosing STIs is critical. Many countries, including the US, have seen a sharp increase in the incidence of STIs over the past half-decade, and especially since 2020. Many cases go undiagnosed and untreated, and 30% of patients may never get treatment after testing positive. Some of these S ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Point-of-care diagnostic test for T. cruzi (Chagas) infection

    SBC: KEPHERA DIAGNOSTICS LLC            Topic: NIAID

    Project Summary Chagas disease, caused by infection with the parasite Trypanosoma cruzi, is the most prevalent parasitic disease in the western hemisphere, infecting 8-11 million individuals and with over 70 million at risk. The infection is transmitted by an insect vector that is native to Latin America, but can also be acquired through blood transfusion, organ transplant, or congenitally. Follow ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Development of a Novel Bone Adhesive Scaffold to Accelerate Bone Regeneration and Improve Ridge Height Maintenance for the Treatment of Patients with Residual Ridge Resorption

    SBC: REVBIO, INC.            Topic: NIDCR

    PROJECT SUMMARY/ABSTRACT Over 50% of US adults over the age of 45 have missing teeth. Following tooth loss, the alveolar portion of the jaw will atrophy in a process known as residual ridge resorption. While dental implant-supported crowns have become the standard of care, market research indicates that 70% of patients must undergo a ridge augmentation procedure to provide adequate bony structure ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. An early-intervention gene-editing therapeutic for Pulmonary Arterial Hypertension

    SBC: HUNTERIAN MEDICINE LLC            Topic: NHLBI

    PROJECT SUMMARY/ABSTRACT Pulmonary arterial hypertension (PAH) is a rapidly progressing pulmonary vascular disease that leads to right heart failure and premature death. The hallmark features of PAH are increased pulmonary arterial pressure, vascular remodeling, and right ventricle hypertrophy. There are no curative treatments for PAH and approximately 1,000 new cases of PAH are diagnosed in the U ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a first-in-class combination of DNA damage response inhibitors for the treatment of high-grade serous ovarian cancer

    SBC: APREA THERAPEUTICS, INC.            Topic: 102

    PROJECT SUMMARY High-grade serous ovarian carcinoma (HGSOC) is a devastating disease responsible for the deaths of ~125,000 women worldwide each year. HGSOC has the lowest survival rates. More than 20% of HGSOCs harbor genetic mutations (e.g. BRCA1/2MUT) that cause defects in homologous recombination (HR), which causes sensitivity to PARPi. However, responses to PARPi are rarely durable and resist ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Virtual Reality Train the Trainer (VRT3)

    SBC: CHARLES RIVER ANALYTICS, INC.            Topic: 500

    Project Summary/AbstractCharles River Analytics proposes to explore the feasibility of a Virtual Reality Train the Trainer (VRT3) program that addresses the critical barriers to appropriately using VR training through a Phase I effort focused on developing training and real-time support for instructors. VRT3 is significant because poorly implemented and delivered VR training can have deleterious t ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Colorimetric Sensor for Detection of Cerebrospinal Fluid Leaks

    SBC: DrinkSavvy, Inc.            Topic: 106

    PROJECT SUMMARY Chemeleon, Inc. is a NYC-based startup that is developing a novel colorimetric biosensor that rapidly diagnoses cerebrospinal fluid (CSF) leaks at the Point-of-Care (POC), such as by doctors to diagnose Traumatic Brain Injury (TBI) patients in the Emergency Department (ED), or the Emergency Medical Technician (EMT) in the ambulance, or during intraoperative and post-operative care ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Development of D6PV- a novel ApoC-II peptide mimetic therapeutic

    SBC: PROTEAN BIO INC            Topic: 300

    PROJECT SUMMARY The goal of the current study is to complete IND enabling studies to develop a therapeutic based on D6PV, a novel ApoC-II peptide mimetic, by conducting toxicology studies and manufacturing GMP drug substance and drug product for future Phase 1 trials in normal healthy volunteers. Successful completion of aims proposed here will result in the development of a novel peptide mimetic ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government